ReviewCureus2025
Efficacy and Safety of Centchroman in the Treatment of Breast Fibroadenoma: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world contraceptive performance of ormeloxifene among reproductive-age women.The Indian journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast fibroadenoma is a benign disease in women of reproductive age group which usually presents as painless, solitary, or multiple lumps located in the same or both breasts. Management of breast fibroadenoma ranges from watchful observation for self-regression to surgical interventions. Many studies have evaluated centchroman for its efficacy and safety in the treatment of breast fibroadenoma, but their findings were conflicting. We, therefore, aimed to conduct this systematic review and meta-analysis to resolve the conflict. The primary objective was to assess the efficacy whereas the secondary objective was to assess the safety of centchroman compared with no intervention-only watchful waiting, placebo or any active control in patients with breast fibroadenoma. The protocol for this systematic review and meta-analysis was designed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.